Compare GCTK & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCTK | ARTL |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.6M |
| IPO Year | 2011 | 2014 |
| Metric | GCTK | ARTL |
|---|---|---|
| Price | $0.37 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.6M | 120.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $589,462.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.71 |
| 52 Week High | $14.14 | $19.91 |
| Indicator | GCTK | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 37.29 |
| Support Level | $0.28 | $0.71 |
| Resistance Level | $0.68 | $1.87 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 19.37 | 26.83 |
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.